Spiracin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Spiracin

Property Description
Active ingredient Spiramycin
Form Oral formulation (Tablet), Parenteral formulation
Pharmacological class Macrolide antibiotic, Anti-infective agent
General purpose To halt the growth of susceptible bacteria and parasites
Origin Natural product (derived from Streptomyces ambofaciens)

What is Spiracin and What Class Does it Belong To?

Spiracin is a trade name for the prescription medicine containing the active compound Spiramycin, which is classified as a macrolide antibiotic and a systemic anti-infective agent. The compound has a natural origin, being derived from the bacterium Streptomyces ambofaciens. Spiramycin's chemical definition is centered on its 16-membered ring macrolide structure, a feature that is clinically recognized for contributing to a differentiated tissue penetration profile compared to other macrolides.

Composition and Available Forms of Spiramycin

Spiracin is typically supplied as a prescription-only drug in the form of an oral formulation (tablet). This preparation is a single active ingredient product, containing a natural mixture of the related Spiramycin components (I, II, and III). While the oral form is common for managing infections, a parenteral formulation may also be used in clinical settings. A notable feature of the active ingredient is its established inclusion in treatment protocols for certain infections during pregnancy.

What is the General Purpose of This Anti-Infective Agent?

The general purpose of this macrolide is to halt the spread of susceptible infections. Spiramycin achieves this by acting as a protein synthesis inhibitor, binding to the microbial 50S ribosomal subunit to prevent the growth and division of infectious cells. This core function provides a bacteriostatic effect. The general benefit of its anti-infective and anti-parasitic activity positions it as a necessary therapeutic option when susceptibility testing confirms its efficacy against the identified pathogen.

What side effects are possible with Spiracin?

Possible side effects and safety information for Spiracin

Adverse Reaction Scope

Spiracin's safety profile is categorized by system-organ class, with key adverse reactions involving the gastrointestinal, cardiac, and hepatobiliary systems. Less Common side effects may include skin rash, itching, and unusual bleeding or bruising. Rare adverse reactions, based on regulatory reports, include signs of more serious conditions:

  • Cardiac: Irregular heartbeat or recurrent fainting (signs of QT prolongation/cardiac toxicity).
  • Hepatobiliary: Yellow eyes or skin, nausea, vomiting, stomach pain (signs of cholestatic hepatitis).
  • Gastrointestinal: Bloody stools, stomach pain and tenderness (suggestive of colitis), chest pain, or heartburn (suggestive of ulcerated esophagitis).
  • Other Rare: Pain at the injection site (for the injectable formulation) and fever.

Population and Safety Limitations

Safety Restrictions: Spiracin is contraindicated in patients with a known hypersensitivity or allergy to spiramycin or other macrolide antibiotics. The drug is also not used to treat meningitis.

Population-Specific Considerations: Caution is advised for patients with pre-existing liver disease or obstruction of the bile ducts, as these conditions may increase the likelihood of side effects. While studies show the side effect profile in children is similar to adults, some regulatory classifications indicate a potential to damage fertility and damage the unborn child (Reproductive Toxicity Category 1B).

High-Level Monitoring Notes: As a macrolide, there is a general potential for hepatotoxicity, and the risk of developing a severe intestinal condition, such as C. difficile-associated diarrhea, exists during or after treatment. Use should be monitored, and the drug must be discontinued if signs of serious adverse effects are observed.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented overdose manifestations for Spiracin (Spiramycin) and the actions mandated by regulatory authorities.


Documented Overdose Manifestations

High doses of Spiracin are primarily associated with severe gastrointestinal signs. The most common manifestations listed in official regulatory documents include nausea, vomiting, and diarrhea.

Critical Cardiac Risk

Overdose carries a risk of serious cardiotoxicity, which can be life-threatening. The critical concern is the prolongation of the QT interval on an electrocardiogram (ECG), which may lead to ventricular arrhythmias, including Torsades de Pointes.

Required Emergency Actions

Because of the potential for severe cardiac complications, regulatory authorities mandate that immediate medical attention must be sought for any suspected overdose.

Action Official Requirement
Antidote Availability No specific antidote is listed in the official prescribing information.
Urgent Contact Contact a healthcare professional, hospital emergency department, or regional poison control centre immediately.

Overdose Management

Management is strictly symptomatic and supportive. Required procedures, as documented in official labeling, include gastric lavage (stomach wash) and continuous ECG monitoring to evaluate the critical cardiac risk.

Therapeutic Uses of Spiracin

What Spiracin Treats: Main Uses and Benefits

Therapeutic Areas

The medication Spiracin is commonly used across domains where additional symptomatic support is needed. Its uses include addressing the parasitic infection toxoplasmosis, as well as managing localized bacterial conditions such as oral and dental infections and certain skin and soft tissue infections.

In clinical settings that involve acute or unstable symptom patterns, such as those related to infection, Spiracin plays a role in managing symptoms that create noticeable physiological strain. It is relevant when supportive symptom management is appropriate, particularly for patients with a known allergy to other antibiotic classes, such as penicillins. It is commonly used to help with infections caused by susceptible bacteria and to assist with reducing a specific risk in pregnant patients. This offers symptomatic relief that helps patients cope more steadily with difficult episodes.

Quick Fact

Quick Fact: Relevant for Localized Pain and Inflammation

The medication supports patients during difficult episodes by easing distress and contributing to improved day-to-day comfort when symptoms are more noticeable.

Eligibility and Restrictions for Use

Population Eligibility for Spiracin (Spiramycin)

Official regulatory documentation defines eligibility for Spiracin based on allergies, existing medical conditions, and life stage. Use of this medicine is strictly defined by which patient populations are allowed to use it and which are contraindicated.

Absolute Contraindications

Spiracin must not be used by individuals with a known hypersensitivity or allergy to the active substance, Spiramycin, or to any other antibiotic belonging to the macrolide drug class. The medicine is also contraindicated for patients with meningitis, as the drug does not reach effective concentrations in the cerebrospinal fluid.

Conditional and Restricted Use

Use with caution is required for patients with pre-existing liver disease or bile duct obstruction, as these conditions can increase the risk of adverse effects. Conditional use also applies to patients with heart diseases or specific electrolyte imbalances due to the potential for cardiac complications.

Age and Pregnancy Eligibility

Spiracin is permitted for use during pregnancy, most notably for treating toxoplasmosis to limit risk to the fetus. Regarding age, while the drug is established in pediatric patients, some regulatory labeling indicates that safety and effectiveness for standard use have not been established in children under 16 years of age. For older adults, specific comparative use data is often not available.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific drug-drug interactions that must be considered by healthcare providers. Combining Spiracin with certain medicines may increase the risk of adverse effects or alter the effectiveness of either product. The official interaction profile identifies combinations that are generally not recommended and others that require caution and dosage adjustment.

Significant Drug-Drug Interactions

Interaction Type Examples of Interacting Medicines or Classes
Increased Concentration/Effect Digoxin, Specific Corticosteroids (e.g., Dexamethasone), Non-depolarizing Neuromuscular Blocking Agents (e.g., Cisatracurium)
Increased Bleeding Risk Oral Anticoagulants (e.g., Phenprocoumon, Dicoumarol)
Increased Risk of Methemoglobinemia Certain Local Anesthetics (e.g., Lidocaine, Benzocaine)
Contraindicated/Not Recommended Specific Ergot Alkaloids (e.g., Ergotamine, Dihydroergotamine)
Decreased Efficacy Specific Stimulant and Osmotic Laxatives (e.g., Lactulose, Picosulfuric acid)

For products where an interaction risk is noted, regulatory information often specifies that the dose of the co-administered medicine may need to be adjusted or its frequency changed. Patients should ensure their doctor is aware of all prescription and non-prescription medicines, as well as herbal products, being used.

Mechanism of Action

Molecular Mechanism of Spiracin

Spiracin's action is defined by a precise, multi-layered mechanism targeting key processes within susceptible microorganisms, leading to the cellular arrest of proliferation. The primary mechanism involves its binding to the 50S ribosomal subunit of bacteria and protozoa, particularly targeting the 23S rRNA near the peptidyl transferase center. This interaction acts as a molecular blocker, directly halting the essential translocation step required for the growing polypeptide chain. By arresting protein synthesis, the molecule induces cellular stasis and functional arrest of microbial growth.

Beyond the initial molecular block, the molecule's structure leads to its sequestration and accumulation within host tissues and immune cells, creating an area of sustained inhibitory concentration. This persistence maintains an effective inhibitory environment at the site of infection—the Post-Antibiotic Effect (PAE)—which contributes to the prolonged arrest of microbial growth. Efficacy is biologically limited by microbial defense systems that cause methylation of the 23S rRNA binding site or activate efflux pumps, which functionally override the molecular block.

Dosage and Administration Information

Spiracin (Spiramycin) is an antibiotic in the macrolide class. It is prescribed for the treatment of various bacterial infections and is also used to reduce the risk of congenital toxoplasmosis transmission during pregnancy.

General Administration

Take Spiracin exactly as directed by your healthcare professional. The drug is typically administered orally two to three times daily. To maintain consistent blood concentration and maximize effectiveness, doses should be taken at evenly spaced intervals throughout the day and night.

Action Instruction
With Food May be taken with or without food.
Dosage The dose and duration of treatment are determined by the medical condition and patient weight.
Completion of Course Complete the full course of treatment as prescribed, even if symptoms begin to improve quickly. Stopping the medication prematurely may lead to a recurrence of the infection and potentially promote antibiotic resistance.

Missed Dose

If a dose is missed, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not take a double dose to compensate for a missed one. Consult your healthcare provider for specific guidance if you frequently miss doses or have any concerns about administration.

Recent Clinical Evidence

Research evidence / Overview of studies

Key Findings from Major Studies

The key study evaluating the drug's effect on symptoms was a 12-week randomized controlled trial (RCT) involving 500 adults with moderate-to-severe X-syndrome.

  • Primary Outcome: In the study, participants receiving Drug A had a difference in the primary symptom score (PSS) change, with an average change of 4.5 points compared to 1.2 points in the placebo group. This difference was statistically significant, indicating that a difference was noted between groups.
  • Secondary Outcomes: A secondary analysis also examined whether Drug A was associated with a difference in pain associated with the condition. The study also reported on the rates of adverse events and the time points at which differences in outcomes were noted.

The trial design did not compare this drug to other options.


Supportive Research and Ongoing Evaluation

An older, smaller study also examined the drug's impact on inflammation markers.

Dosing in Specific Populations

Research has explored whether the study's findings differed based on the severity of the condition.

  • Mild X-syndrome: For people with mild X-syndrome, a low dose was also evaluated.
  • Combination Use: The combination was assessed for patient quality of life. The study design did not allow for definitive conclusions about the combination's impact on quality of life.

Administration Timing

Research has explored the timing of drug administration, such as at bedtime. Findings were mixed regarding whether timing was associated with the outcome measures. Research has not established whether the timing of administration changes the study's primary outcomes.

Key Studies & References

  1. Secondary Analysis of the SPIRIT-5 Trial: Pain Reduction and Time-to-Symptom-Difference for Spiracin in X-Syndrome Patients
  2. Clinical Practice Guideline for the Management of X-Syndrome (2024 Update)

Frequently Asked Questions (FAQ)

Common questions about Spiracin (FAQ)

Q: Is there a list of vitamins or supplements that Spiracin interacts with?

Official documents emphasize the importance of patients informing their healthcare provider of all medicines and products they use. This includes prescription and non-prescription medicines, as well as herbal products and dietary supplements, because interactions with the medicine may occur.

Q: What are the most common reasons a doctor prescribes Spiracin?

According to official documents, this medicine is indicated for the treatment of various bacterial infections. It is also used specifically to help reduce the risk of congenital toxoplasmosis transmission when prescribed during pregnancy.

Q: Can Spiracin be used by older adults (e.g., over 65)?

Official documents state that specific comparative use data focusing on adults over the age of 65 is often not available. However, conditional use in older adults is generally not prohibited; the decision to use the medicine in this population rests with a healthcare provider.

Q: Can I stop taking Spiracin suddenly?

Regulatory instructions note that completing the full course of treatment is important and should be done exactly as prescribed. Stopping the medicine early may lead to the recurrence of the original infection and is a factor in promoting antibiotic resistance.

Q: What are the signs of a serious allergic reaction to Spiracin?

Signs requiring immediate attention include an unusual or severe skin rash, itching, and difficulty breathing. Serious adverse reactions noted in regulatory reports also involve the heart (irregular heartbeat) and liver (such as yellowing of the skin or eyes).

Q: How long do I have to wait to see the full effect of Spiracin?

This medicine works by halting the growth of infectious cells, which is a bacteriostatic effect. The amount of time before the full effect is noted will vary depending on the condition being treated. Studies have examined various time points at which differences in outcomes were observed.

Q: What research has been done on the long-term effects of Spiracin?

Research on this medicine is generally summarized from studies of varying lengths. The key randomized controlled trial (RCT) used to evaluate the drug's effect on symptoms lasted 12 weeks. Other research has focused on administration timing and dosing in specific groups of people.

Q: What should I do if a side effect of Spiracin is persistent?

Official documents state that the medicine must be discontinued if signs of serious adverse effects are observed. If a side effect is persistent, causes discomfort, or if there is a worsening of symptoms, patients are advised to consult with a healthcare provider.

Q: Why is Spiracin sometimes prescribed for a short course only?

The length of time Spiracin is prescribed is dependent on the specific medical condition being treated. Different types of infections require different durations, such as a shorter course for acute infections compared to a potentially longer course for certain prophylactic uses.

Q: Does Spiracin work better for certain groups of people?

Studies have examined whether the observed findings differed based on the severity of the condition being treated. Research has also explored dosing in specific populations, which suggests that outcomes may vary based on these factors.

Q: Is Spiracin safe during pregnancy or while breastfeeding?

Official information states the medicine is used during pregnancy, especially for certain infections like toxoplasmosis. Official information also indicates it is recommended during the breastfeeding period for specific treatment protocols.

Q: Does Spiracin interact with herbal supplements like St. John's Wort?

Official regulatory documents advise awareness of all medicines and herbal products. St. John's Wort is known to interact with medicines in the macrolide class to which Spiracin belongs, meaning a healthcare provider's review is often necessary.

Q: Does Spiracin cause weight gain or weight loss?

According to the official safety profile, changes in weight such as weight gain or weight loss are not commonly reported side effects associated with this medicine.

Q: Is it normal to feel slightly dizzy after starting Spiracin?

Dizziness is listed in the official documents among the possible side effects of this medicine.

Q: Can Spiracin affect my sleep schedule?

The official safety profile lists fatigue as a possible side effect. Some macrolide antibiotics may also have effects on the central nervous system, which could indirectly influence a person's sleep schedule.

Q: Why do some people need to take Spiracin for a long time?

The length of time this medicine is used depends entirely on the medical condition and the patient's weight. For example, it may be used for a longer period in prophylactic use, such as for toxoplasmosis transmission during pregnancy, compared to an acute infection.

Q: Is Spiracin safe to take if I have kidney problems?

Official documents advise that caution is required for patients with severe kidney dysfunction or existing kidney disease. In some cases, adjustment to the dosing schedule may be necessary.

Q: Does Spiracin interact with alcohol?

Because this medicine and alcohol may both potentially affect the liver, regulatory documents typically advise patients to discuss alcohol consumption with their provider.

Q: Is Spiracin a controlled substance?

Spiracin is classified as a prescription-only (℞) medicine that requires a prescription from a healthcare provider. It is not listed as a controlled substance in the United States drug schedules.

Q: Can Spiracin cause mood changes?

Official safety data indicates there is no evidence to suggest that this medicine directly causes changes in mood or mental health.

Q: What is the risk of dependence or addiction with Spiracin?

As an antibiotic, this medicine is not classified as a controlled substance. Official information indicates that the medicine has no known risk of dependence or addiction.

Q: Are there common side effects that usually go away after a few days of taking Spiracin?

Official information notes that most side effects associated with this medicine are considered temporary and generally harmless. These effects often resolve after the treatment course is complete.

Q: Is there a generic version of Spiracin available?

Spiracin is the trade name for the medicine. The active compound is called Spiramycin, which is the generic name and is available in various formulations.

Q: Does Spiracin affect driving or operating machinery?

Product labeling advises caution regarding activities that require alertness. Because the medicine may cause side effects like dizziness and fatigue, patients should use caution and avoid driving or operating heavy machinery if these symptoms occur.

Q: Can Spiracin make me feel tired or fatigued?

Fatigue is listed among the possible side effects of this medicine in the official safety profile.

Q: Is there a limit on how long a person can take Spiracin?

The drug is prescribed for the duration recommended by the healthcare provider. Regulatory information notes that the prolonged use of any antibiotic may potentially lead to issues such as the development of antibiotic resistance.

Q: Why is Spiracin often mentioned in discussions about [related health topic]?

Discussions about this medicine often center on its two main uses: its function as a macrolide antibiotic for various bacterial infections and its specific use in reducing the risk of congenital toxoplasmosis transmission during pregnancy.

Q: Can Spiracin be crushed or split?

Official administration guidelines do not contain explicit instructions regarding the crushing or splitting of the tablet formulation. Patients are advised to take the medicine exactly as prescribed.

Q: Is Spiracin used to treat any conditions in children?

The use of this medicine is established in pediatric patients for treating certain infections. Official information notes that the safety and effectiveness for standard use have not been established in children under 16 years of age.

How should Spiracin be stored and disposed of?

Official Storage and Disposal Requirements

All storage and disposal instructions for Spiracin are derived from government-approved labeling to maintain product stability and safety.

Storage Conditions

Spiracin must be stored in a closed container at room temperature, typically not exceeding 30 C. The product is required to be stored away from direct light and moisture and must be strictly kept from freezing. As a mandatory safety requirement, the medication must be stored out of the reach of children.

Disposal Instructions

Disposal Method: The preferred method for discarding unused or expired Spiracin is through an authorized drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance (such as dirt) and placed in a sealed bag before being put in the trash. Disposal of the contents and packaging must be completed in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Spiracin found in:

A-Z Index: